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Interferon lambda 3 (IFNL3, previously called IL-28B) is a cytokine with effects against
viral and bacterial pathogens. We aimed to analyze the IFNL3 rs12980275 SNP
in patients who underwent major surgery, in order to establish its relationship with
susceptibility to septic shock and septic shock-related death in these patients. We
performed a case-control study on 376 patients to establish the association between
IFNL3 rs12980275 SNP and the susceptibility to develop septic shock. Besides, we
performed a longitudinal study among 172 septic shock patients using survival analysis
with one censoring point of 28-days mortality. The IFNL3 rs12980275 polymorphism
was genotyped by Agena Bioscience’s MassARRAY platform. IFNL3 rs12980275
polymorphism was not associated with higher susceptibility to infection and septic
shock development. Regarding survival analysis, the Kaplan–Meier analysis showed that
patients with IFNL3 rs12980275 AA genotype had higher survival than patients with GG
genotype (p = 0.003). The Cox regression analysis adjusted by the most relevant clinical
and epidemiological characteristics showed that the GG genotype (recessive model) and
the presence of the G allele (additive model) were associated with higher risk of death
[adjusted hazard ratio (aHR) = 2.15, p = 0.034; aHR = 1.50, p = 0.030, respectively]. In
conclusion, IFNL3 rs12980275 polymorphism was associated with septic shock-related
death in patients who underwent major surgery. The A allele was linked to protection,
and the G allele was associated with an increased risk of death. This is a first preliminary
study that suggests for the first time a role of IFNL3 polymorphisms in the prognosis of
septic shock.
Keywords: IFNL3, rs12980275, SNP, sepsis, septic shock, survival, major surgery
Pérez-García et al. rs12980275 SNP and Septic Shock-Related Death
INTRODUCTION
Sepsis is a life-threatening disease, defined as a syndrome of
organ dysfunction due to a dysregulated host response to an
infection (1). Septic shock is defined as the most severe stage
of sepsis, in which the underlying circulatory, cellular, and
metabolic abnormalities are enough to increase mortality (1). In
the last years, the incidence of sepsis has grown worldwide and
has been reported as the most common cause of Intensive Care
Unit (ICU) admission (2). This disease affects more frequently
elderly patients, being especially common in patients with cancer
or underlying immunosuppression (3). Regarding the incidence
of sepsis, a recently published study estimated the incidence
of sepsis about 48.9 million worldwide, estimating also sepsis-
related death in 11 million (4). Although sepsis-related death is
decreasing in the last years (4, 5), it remains unacceptably high,
accounting as the most frequent cause of death in ICU patients,
and constituting a significant cost for healthcare systems (6). An
early and accurate diagnosis, in addition to adequate treatment,
are crucial elements to reduce sepsis development (7). Moreover,
the research of predictors of morbidity and mortality constitutes
a priority in order to provide adequate management of patients
with sepsis (8).
Sepsis is related to an inadequate immune response due
to excessive inflammation that leads to organ dysfunction and
multi-organ failure in the most severe cases (9). There are several
pro-inflammatory cytokines (such as TNF, IL-1, IL-6, and IL-
17), cell surface markers (for example, CD14) and transcription
factors [nuclear factor-kappaB (NF-κB)] that are involved in the
inflammatory response against infection and are also related to
the pathophysiology of sepsis (9–11). The interferon lambda
(IFNL or IFN-λ, also called type III IFN) family is composed
of four IFNLs, IFNL1–4 (12). Interferon lambda 3 (IFNL3,
previously called IL-28B) is a cytokine that modulates the
immune response against viral and bacterial pathogens (12, 13).
IFNL3 acts through its receptor (IFNLR1), which is mostly
expressed by cells of epithelial origin and immune cells, inducing
the expression of over 300 interferon-stimulated-genes (ISGs)
(12, 13).
The vast majority of published research has focused on the
contribution of IFNL3 to the anti-viral host defense, but IFNL3
has also been implicated in the anti-bacterial immune responses
such as Staphylococcus aureus, Pseudomonas aeruginosa, and
Listeria monocytogenes (13). Planet et al. (14) found that infection
with the influenza virus and the subsequent activation of the
IFNL3 signaling pathway led to an increased susceptibility
to pulmonary infection by methicillin-resistant Staphylococcus
aureus. Luo et al. (15) showed that IFNL3 levels were significantly
higher in patients with sepsis and septic shock patients that
died, compared with healthy controls and septic shock survivors,
respectively. Besides, these authors showed in experimental septic
models that the supplementation with IFNL3 worsened the
outcome of sepsis, and the neutralization of IFNL3 activity
with specific antibodies increased the sepsis survival and a
decrease in neutrophil infiltration, (15). Additionally, Cohen and
Prince (16) showed mice lacking IFNLR, when compared with
controls, significantly improved the clearance of S. aureus and
P. aeruginosa, and that it was also associated with a decrease in
the duration of the inflammatory response.
The clinical impact of single nucleotide polymorphisms
(SNPs) at the IFNL3 gene has been described principally in
the context of hepatitis C, being rs12979860, rs8099917, and
rs12980275 the most-frequently related to spontaneous hepatitis
C virus (HCV) clearance (17). These IFNL3 SNPs are in high
linkage disequilibrium (LD) between them and with other SNPs
in IFNL4 (12, 18). Moreover, IFNL3 SNPs have also been
associated with the prognosis of different viral infections (12),
such as Andes virus, BK virus, cytomegalovirus, herpes simplex
virus (HSV), and human T-lymphotropic leukemia virus (HTLV)
type I, among others. However, the association of IFNL3 SNPs
with the dysregulated inflammatory response in patients with
sepsis has not been reported so far.
Our study aimed to analyze the IFNL3 rs12980275 SNP in
patients who underwent major surgery in order to establish its




We performed a case-control study, including patients from
the Hospital Clínico Universitario of Valladolid (Spain). The
study population consisted of patients that underwent major
surgery, which was defined as any surgical procedure (abdominal
or cardiac) that was performed under general anesthesia and
respiratory assistance. A total of 376 patients were selected
between April 2008 and November 2012 and stratified as follows:
(a) 172 patients who developed an infection after the surgery
(with positive culture) and a subsequent septic shock (SS-
group); (b) 204 patients without infection but who developed a
systemic inflammatory response syndrome (SIRS-group), which
is a frequent condition after this kind of surgeries. Additionally,
the survival at 28-day was analyzed in patients belonging to
the SS-group.
The study was conducted according to the ethical
requirements established by the Declaration of Helsinki.
The Ethics Committee of Hospital Clínico Universitario de
Valladolid and Instituto de Salud Carlos III approved the study.
Written informed consent was provided by all participants
before sample collection. When a patient was unable to sign,
a family member or legal representative of the patient signed
the consent.
Clinical Data
Epidemiological and clinical data were retrieved from medical
records. Emergency surgery was indicated for life-threatening
conditions such as aortic dissection, heart and postoperative
bleeding, and intestinal perforation.
Septic shock and SIRS diagnoses were established according to
SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions
Conference criteria (19), which was in effect when the data
and samples were collected. Subsequently, we updated them
according to Sepsis-3 definitions (20). The septic shock diagnosis
was made during the entire follow-up time post-surgery, and
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it was defined as an acute circulatory failure with persistent
arterial hypotension that required vasopressor to maintain a
mean arterial pressure of 65 mmHg or greater and serum lactate
level greater than 18 mg/dL. SIRS diagnosis was made within
the first 24 h post-surgery, as an inflammatory response to a
noninfectious cause, and therefore, the infection in this group
was ruled out.We selected the SIRS group as a control group with
similar age and gender, which underwent to the same conditions
as the case group (major surgery), but they did not develop
sepsis. Finally, we confirmed that no patient had infection before
major surgical intervention and all septic shock patients had a
microbiologically confirmed infection.
Moreover, Acute Physiology and Chronic Health Evaluation
(APACHE II score) and Sequential Organ Failure Assessment
(SOFA score) were calculated for both groups, in order to assess
the severity of the condition within the first 24 h following
septic shock diagnosis. The choice of the most appropriate
antibiotic therapy, as empiric treatment for sepsis, was based on
our experience regarding the most common bacterial pathogens
associated with sepsis in our medical ICU, and also according to
international guidelines (21).
DNA Genotyping
Blood samples for DNA genotyping were collected from all
patients who underwent major surgery between 2008 and 2012.
Total DNA from peripheral blood was extracted using the High
Pure PCR Template Preparation kit (Roche Diagnostics GmbH,
Mannheim, Germany). The rs12980275 SNP the was genotyped
at the Spanish National Genotyping Center (CeGen; http://www.
cegen.org/) by the Agena Bioscience’s MassARRAY platform
(San Diego, CA, USA) using the iPLEX R© Gold assay design
system (https://agenabio.com/products/massarray-dx/).
Outcome Variables
We analyzed two main outcome variables: (i) susceptibility to
develop septic shock (case-control study); (ii) mortality after
diagnosis of septic shock (longitudinal sub-study) with one
censoring point at 28-days, which is a commonly used primary
endpoint for clinical trials that study the usefulness of new
therapeutic approaches in severe sepsis patients (22).
Statistical Analysis
Quantitative variables were expressed as the median and
interquartile range (IQR), and categorical variables were
expressed as absolute count (percentage). Comparisons between
groups in the descriptive analysis of the study population
were made using the Mann-Whitney U-test for continuous
variables and the Chi-squared or two-tailed Fisher’s exact test
for categorical variables. A p ≤ 0.05 was considered significant.
The IFNL3 SNP was analyzed for deviation from the Hardy–
Weinberg equilibrium (HWE), where p < 0.05 was considered
to be statistically significant.
Regarding the genetic association study, analyses were carried
out for dominant, recessive and additive models. In the case-
control study (Septic shock-group vs. SIRS-group), logistic
regression was performed to investigate the association between
IFNL3 SNP and the development of septic shock. In the
TABLE 1 | Demographic and clinical characteristics of patients with SIRS
(SIRS-group) and with septic shock (SS group) who underwent major surgery.
Characteristics SIRS-group SS-group p-value
No. of patients 204 172 –
Gender (male) 130 (63.7%) 110 (64.0%) 1.000
Age (years) 72 (65–78) 74 (63–80) 0.526
Underlying conditions
Smoker 26 (12.8%) 30 (17.4%) 0.245
Alcoholism 6 (2.9%) 10 (5.8%) 0.204
Obesity 22 (10.8%) 26 (15.1%) 0.219
Diabetes 40 (19.6%) 22 (12.8%) 0.094
Heart disease 118 (57.8%) 79 (45.9%) 0.023
COPD 29 (14.2%) 28 (16.3%) 0.665
Hypertension 123 (60.3%) 96 (55.8%) 0.402
Chronic kidney
disease
12 (5.9%) 27 (15.7%) 0.002
Cancer 76 (37.3%) 41 (23.8%) 0.005




112 (54.9%) 71 (41.3%) 0.010
Emergency (vs.
scheduled)
19 (9.3%) 107 (62.2%) <0.001
Severity indexes
SOFA score 3 (3, 4) 9 (7–11) <0.001
APACHE II score 9 (8–10) 17 (13–20) <0.001
Statistics: Values are expressed as median (percentile 25-percentile 75) and absolute
count (percentage). *P-values were calculated by Fisher’s exact test for categorical
variables and Mann-Whitney test for continuous variables. Significant differences are
shown in bold. Abbreviations: SIRS, systemic inflammatory response syndrome; p-value,
level of significance; COPD, Chronic obstructive pulmonary disease; SOFA, sequential
organ failure assessment; APACHE, acute physiology and chronic health evaluation.
longitudinal sub-study, a survival analysis was used to evaluate
mortality at 28 days after septic shock diagnosis. Survival
probabilities were estimated by the Kaplan–Meier product-
limit method, and groups were compared using the log-
rank test. The multivariate Cox regression test was adjusted
by the most significant covariates, which were selected by a
stepwise method (forward), from the following variables: age,
gender, antibiotic treatment, peritonitis, hypertension, lactate,
comorbidities [obesity, diabetes, chronic kidney disease, heart
disease, chronic obstructive pulmonary disease (COPD), cancer,
and liver disease], SOFA score, and type of surgery (emergency
vs. scheduled; cardiac vs. abdominal). Statistical analysis was
performed using Stata/IC 13.1 (StataCorp, Texas, USA).
RESULTS
Susceptibility to Septic Shock
The demographic and clinical characteristics of the selected 376
patients are summarized in Table 1. Briefly, patients of the SS-
group (n = 172) had higher percentages of chronic kidney
disease, higher values of SOFA and APACHE II score, and
required abdominal and emergency surgery more frequently.
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FIGURE 1 | Genetic association of IFNL3 rs12980275 polymorphism with susceptibility to septic shock and shock-related death in patients who underwent major
cardiac or abdominal surgery. (A) SIRS-group vs. SS-group. (B) Alive vs. exitus patients. Statistics: P-value was calculated by logistic regression analysis.
Abbreviations: IFNL3, Interferon lambda 3; SIRS, systemic inflammatory response syndrome; SS, septic shock; SNP, single nucleotide polymorphism.
On the other hand, patients of the SIRS-group (n = 204)
presented higher percentages of heart disease, cancer, and
cardiac surgery.
The rs12980275 polymorphism had a minor allelic frequency
(G vs. A) higher than 10% and fulfilled the HWE (p > 0.05).
The genotypic frequencies of IFNL3 rs12980275 polymorphism
were very similar between the SS-group and the SIRS-group
(Figure 1A).
The rs12980275 polymorphism was not associated
with susceptibility to the development of septic shock,
regardless of the inheritance model analyzed. For this
reason, it was omitted from the multivariate logistic
regression analysis.
Risk of Death in Patients With Septic Shock
The baseline characteristics of septic shock patients stratified by
alive vs. exitus are shown in Supplementary Table 1. Patients
who died were older, had higher lactate values and SOFA and
APACHE II scores, and higher percentages of emergency surgery
and chronic kidney disease (p < 0.05). Ninety-seven percent of
patients had adequate initial empirical treatment according to
the antibiogram data. Moreover, all patients survived in the SIRS
group during the follow-up period (28 days).
The genotypic frequency of IFNL3 rs12980275 polymorphism
was different between alive and dead patients with septic shock
during the first 28 days after septic shock diagnosis (Figure 1B),
according to the three inheritance models analyzed, which
suggests an association of this polymorphism with death at 28
days in ICU. The Kaplan-Meier analysis (Figure 2 and Table 2)
showed that patients with IFNL3 rs12980275 AA genotype had
higher survival than patients with GG genotype (p = 0.003).
The Cox regression analysis adjusted by the most relevant
clinical and epidemiological characteristics showed that the
G allele [either in a recessive model (GG) or additive (G)]
was associated with a higher risk of death [adjusted hazard
ratio (aHR) = 2.15, p = 0.034; aHR = 1.50, p = 0.030,
respectively; Table 2].
DISCUSSION
Our study shows that IFNL3 rs12980275 polymorphism was not
associated with susceptibility to the development of septic shock,
but a significant association with the risk of death at 28 days
in septic shock patients was found. The A allele was linked to
protection and the G allele was associated with an increased risk
of death. To the best of our knowledge, this is the first study that
points out the relationship between IFNL3 SNPs and death in
septic shock patients.
IFNL SNPs at transcription factor binding sites, promoter
regions, methylation sites, and frameshift mutations, seem to
modulate IFNL expression (12, 18). Specifically, rs12980275 is
located in a downstream region of IFNL3 and IFNL4 genes
and could be implicated in the regulation of gene expression
since rs12980275 seems to influence the chromatin state (23).
However, the search for the causal IFNLmutation is complicated,
as SNPs within IFNL3 gene are in high LD with other SNPs at
IFNL4. Thus, the relationship between IFNL3 SNPs and plasma
IFNL3 levels is still not clear, since the different authors that
have addressed this issue have reached discrepant results (12, 18).
Moreover, minor alleles at IFNL3 SNPs have been associated with
ISG expression, suggesting that the immune response depends
on the IFNL3 SNPs (12, 13, 18). This last finding seems to be
related to other SNPs that regulate the production of IFNL4
(18). As proposed by Bhushan and Chinnaswamy (18), the
presence of the major IFNL3 alleles (rs12979860C allele and
others in LD such as rs12980275A allele) are linked to the IFNL4
rs11322783 (previously called rs368234815) TT allele, which
avoids the expression of a functional IFNL4 protein, generating
a set of ISGs that could result in a protective phenotype against
infection (18). On the other hand, the presence of the minor
IFNL3 alleles (rs12979860 T allele and others in LD such as
rs12980275G allele) are linked to the IFNL4 rs11322783 1G
allele, which is responsible of a fully functional IFNL4 protein
expression, generating another set of ISGs that could result in
a risk phenotype against infection (18). Therefore, taking into
account what was discussed above, we can hypothesize that the
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FIGURE 2 | Survival analysis (Kaplan–Meier curve) regarding to IFNL3 rs12980275 polymorphism in septic shock patients who underwent major cardiac or abdominal
surgery. Statistics: P-value was calculated by log-rank test. Abbreviations: IFNL3, Interferon lambda 3; SNP, single nucleotide polymorphism.
TABLE 2 | Survival probabilities at 28 days (Kaplan–Meier product-limit method) and risk of death in septic shock patients (Cox regression) who underwent major cardiac
or abdominal surgery according to IL-28B rs12980275 SNP.
Kaplan–Meier Cox
Model Genotype N Deaths p-value aHR (95%CI) p-value
Dominant AA 91 25 (27.5%) 0.009 1.54 (0.91–2.61) 0.107
AG/GG 81 36 (44.4%)
Recessive AA/AG 154 50 (32.5%) 0.019 2.15 (1.06–4.35) 0.034
GG 18 11 (61.1%)
Additive AA 91 25 (27.5%) 0.003 1.50 (1.04–2.18) 0.030
AG 63 25 (39.7%)
GG 18 11 (61.1%)
Statistics: values are expressed as absolute count and percentage, and hazard ratio and 95% confidence interval. Significant differences are shown in bold. Abbreviations: aHR, adjusted
hazard ratio; 95%CI, 95% confidence interval; p-value, level of significance; SNP, single nucleotide polymorphism; Cox, regression analysis adjusted by the most significant clinical and
epidemiological characteristics.
IFNL3 rs12980275 AA genotype may be associated with a better
outcome in patients with septic shock, decreasing the risk of
death at 28 days.
Sepsis is a complex syndrome related to an excessive and
inadequate immune response that may lead to organ dysfunction
and multi-organ failure (10). Therefore, IFNL could be one of
the mechanisms that modulate the inflammation and control
pathogens in septic patients. Formajor surgery patients, the study
of their genetic profile and the implementation of predictive
models could help clinicians to identify those patients with septic
shock related death. However, this hypothesis must be confirmed
by further studies covering the analysis of serum levels of
cytokines, gene expression products, and IFNL3 polymorphisms
in patients with sepsis.
LIMITATIONS OF THE STUDY
Firstly, this study had a retrospective design and it was conducted
in one single hospital, only including patients that underwent
major cardiac or abdominal surgery. Due to this fact, our
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conclusions cannot be generalized to other septic patients.
In order to overcome these limitations, further multi-centric
studies, including patients from all kinds of ICUs, would be
necessary. Secondly, we have a low sample size which limited
the statistical power of this analysis and could explain the lack
of association of IFNL3 rs12980275 SNP with susceptibility
to septic shock. Additionally, the low sample size could also
increase the rate of false positives. Thirdly, regarding the survival
analysis, it was performed with only one censoring point of
28-days mortality, but this censoring point day 28 is more
appropriate than others (such as 7 or 90 days) to establish
sepsis-related death (24). Fourthly, as a high LD exists between
IFNL1-4 polymorphisms, we interpreted that our results could
be extrapolated to the linked IFNL SNPs. However, additional
studies analyzing other SNPs in IFNLwould be needed to confirm
our results. Finally, another interesting analysis that we have not
performed was to corroborate our results, that is, to identify the
biological function of the individual SNPs of IFNL3/4. However,
these research are out of the scope of our study and also constitute
tasks that are quite complex and that have been investigated for
a long time, more than a decade, by a large number of scientists
without reaching conclusive results (12, 13, 18).
CONCLUSIONS
In conclusion, IFNL3 rs12980275 polymorphism was associated
with septic shock-related death in patients who underwent major
surgery. This is a first preliminary study that suggests for the first
time a role of IFNL3 polymorphisms in the prognosis of septic
shock. However, since the statistical power of this study was low,
more research is needed to corroborate our findings.
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